ArticleCardiology research2025
Anti-Oxidative Effect of Dapagliflozin, a Selective Sodium Glucose Transporter-2 Inhibitor, for Cardio-Renal Protection in Patients With Heart Failure With Reduced Ejection Fraction.
Article in Cardiology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Selective sodium glucose transporter-2 inhibitor (SGLT2i) has cardio-renal protective effects via osmotic diuresis and natriuresis, and other pleiotropic effects, such as anti-oxidative, anti-fibrotic, and anti-senescence effects, have been suggested. However, those pleiotropic effects have not yet been fully elucidated in a clinical study. Methods: We investigated the effects of SGLT2i in patients with heart failure with reduced ejection fraction (HFrEF). Twenty-five HFrEF patients who were initially treated with dapagliflozin from 2021 to 2023 at Fukuoka University Hospital were enrolled and we investigated their baseline characteristics, medications, clinical laboratory examination findings, echocardiography findings, and additional pleiotropic serum markers before administration of dapagliflozin and 6 months later. Results: The patients were 67.0 ± 13.6 years old, 64.0% were male, and their body mass index was 24.0 ± 4.5 kg/m Conclusions: Dapagliflozin had anti-oxidative effects in patients with HFrEF, in addition to cardio-renal protective effects. These anti-oxidative effects could be related to the cardio-renal protective effects of SGLT2i, even in a clinical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.